Clovis Oncology (CLVS) Release: Ongoing Phase I Monotherapy Study of Rucaparib in Patients With Solid Tumors Demonstrates Clinical Activity, Establishes Dose and Schedule
9/30/2013 10:40:22 AM
BOULDER, Colo.--(BUSINESS WIRE)--Clovis Oncology (NASDAQ:CLVS) today announced updated results from an ongoing Phase I/II monotherapy study of rucaparib, the Company’s oral, potent, small molecule poly (ADP-ribose) polymerase (PARP) inhibitor being developed for the treatment of ovarian cancer. Data from the Phase I dose-escalation portion of this Phase I/II study are being presented today at a poster session during the European Cancer Congress 2013 in Amsterdam. "We’ve seen significant clinical activity with one complete response in breast cancer and six partial responses in ovarian, breast and pancreatic cancers to date, and a disease control rate in patients with germline BRCA mutant ovarian (platinum-sensitive and platinum-resistant) cancer of 100% and 63% at 12 and 24 weeks, respectively. I am pleased to be participating in the Phase II and pivotal Phase III trials (ARIEL2 and ARIEL3) which aim to build on the clear activity of rucaparib in BRCA-mutant ovarian cancer and prospectively identify and test other genetic mutations associated with sensitivity to PARP inhibition in ovarian cancer. This approach has the potential to broaden applicability of PARP inhibitor treatment for ovarian cancer as well as other solid tumors and hopefully benefit many patients,” said Dr. Rebecca Kristeleit, Clinical Senior Lecturer and Consultant Medical Oncologist UCLH and UCL Cancer Institute in London.
Help employers find you! Check out all the jobs and post your resume.